BPK Bespak

RNS Number:0493U
Bespak PLC
14 November 2005


For immediate release                                          14 November 2005



                                   Bespak plc

               Trading update for the 26 weeks to 29 October 2005


Bespak plc (LSE: BPK), a leader in specialty medical devices, announces that
trading in the first half was in line with its expectations. There has been
replenishment of the CFC valve supply chain in the US following the FDA ruling
on phase-out of CFC albuterol formulations, continuing growth in HFA valve sales
and inventory building by customers of US-manufactured products in advance of
closure of the Cary facility.


Looking ahead, two key events will continue to influence Bespak's performance.
Firstly, customers in the US are continuing to develop their marketing plans for
the replacement of CFC with HFA in albuterol formulations by December 2008.
Secondly, Bespak awaits the approval of Exubera(R). In September the FDA's
clinical advisory panel recommended approval of Exubera(R) in the US, whilst in
October the Committee for Medicinal Products for Human Use (CHMP) of the EMEA
recommended approval of Exubera(R) in Europe.


In the second half, we expect additional expenditure to strengthen the
businesses, general inflationary cost pressures and reversal of inventory
building by customers of previously US-manufactured products that have been
transferred to the UK, which leads us to be cautious in the short term. However,
we are increasingly confident in the prospects for growth from Exubera(R).


Bespak will report its interim results on 18 January 2006.


For further information, please contact:


Bespak plc                                             Tel: +44 (0) 1908 525 241

Mark Throdahl - Chief Executive
Martin Hopcroft - Group Finance Director

Buchanan Communications                                Tel: +44 (0) 20 7466 5000

Tim Thompson / Mark Court / Mary-Jane Johnson


About Bespak plc

Bespak, a specialty medical devices company, is at the forefront of developing
new delivery systems for the pharmaceutical industry. The company has a product
range covering metered dose inhalers, dry powder devices, actuators and
compliance aids. The company also develops and manufactures drug delivery
devices for leading global pharmaceutical companies. The group, which has
facilities in King's Lynn and Milton Keynes in the UK, is a public company
quoted on the Official List of the London Stock Exchange (LSE: BPK). For more
information, please visit www.bespak.com.





                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

TSTZGMMMNMZGKZM

Bespak (LSE:BPK)
Historical Stock Chart
From Jun 2024 to Jul 2024

Bespak (LSE:BPK)
Historical Stock Chart
From Jul 2023 to Jul 2024